-
2024-514022-23-00
4
2023-06-23
Early breast cancer
-
2022-502415-11-00
5
2023-06-16
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
-
2023-505634-94-00
10
2023-02-02
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
-
2023-505065-91-00
4
2023-01-30
Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small C
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-517382-17-00
4
2022-11-30
Newly Diagnosed Multiple Myeloma in patients eligible for stem cell tr
-
2023-507041-28-00
4
2022-11-28
Solid and Hematological Malignancies
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-505347-38-00
9
2022-06-13
B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
-
2023-503651-10-00
7
2022-05-17
Male and female participants ≥ 18 years of age with advanced or
metast
-
2024-517334-18-00
6
2022-04-06
Inflammatory or autoimmune disorders
-
2023-508963-58-00
4
2022-01-31
Symptomatic hypertrophic cardiomyopathy (HCM)
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2024-517300-10-01
5
2020-12-17
Resectable diffuse type gastric and gastroesophageal junction Typ II/I
-
2024-510616-73-00
5
2020-12-16
newly diagnosed WHO grade 2 or 3 glioma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer